PHARMACY

Kerr Drug encourages patients to talk to their pharmacists

BY Alaric DeArment

RALEIGH, N.C. — Kerr Drug is launching a new campaign to get people to talk to their pharmacists, the chain announced.

Kerr said it would launch the "Just Ask" marketing campaign in stores and across various marketing channels to encourage its pharmacists and patients to talk to each other about prescriptions, conditions, health practices and overall health.

"I know from working as a pharmacist that there are many reasons people don’t ask about their medicines, including confusion, embarrassment or the patient just not wanting to bother the pharmacist," Kerr CEO Tony Civello said. "The ‘Just Ask’ campaign will encourage conversations and a sharing of information because it’s the best way to avoid poor health outcomes."

Kerr noted that surveys have shown 3-in-4 people don’t always take their medicines as directed, which can lead to serious health consequences, higher medical costs and longer recovery times. Kerr’s campaign will focus on 11 conditions, such as cardiovascular diseases and diabetes, and specific questions a patient might have, such as a medication’s name and what it does; when and how to take it; how patients can save money with generics or other changes; side effects; interactions between medications and other medications, foods and alcohol; what happens when a dose is missed; and how long a patient has to take a medicine.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA grants priority review to Gilead’s Truvada for HIV prevention

BY Alaric DeArment

FOSTER CITY, Calif. — The Food and Drug Administration is giving priority review to a drug made by Gilead Sciences that the company is investigating for the prevention of HIV.

Gilead said the FDA gave the special designation to its application for Truvada (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis, or PrEP, to reduce the risk of HIV infection. The FDA originally approved Truvada for treating HIV infection in 2004, and it is currently the most prescribed antiretroviral drug in the United States.

Gilead said that if approved, Truvada would be the first drug indicated for reducing the risk of acquiring HIV. The company’s regulatory filing, which it submitted on Dec. 15, is based on results of a study sponsored by the National Institutes of Health and the University of Washington that supported the use of Truvada in reducing the risk of HIV infection.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bristol-Myers Squibb completes Inhibitex acquisition

BY Allison Cerra

NEW YORK — Bristol-Myers Squibb has completed its acquisition of a developer of hepatitis C treatments.

Bristol said it successfully completed its tender offer for all of the outstanding shares of common stock of Alpharetta, Ga.-based Inhibitex, at a purchase price of $26 per share via a “short form merger” in which all such shares were converted into the right to receive the aforementioned share price in cash and without interest, less any applicable withholding taxes.

Bristol said it intends to delist and de-register Inhibitex common stock as promptly as practicable following the effective time of the merger.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?